AI CuratorAI-generated
Research summary · AI summary · not yet reviewedHuman studyPhase 1/2Trial registry record – peer review not applicable
C-CAR168 in Progressive Multiple Sclerosis: A Phase 1/2 Study
A Phase 1b/2 study evaluated the safety and efficacy of C-CAR168, an autologous therapy, in individuals with progressive multiple sclerosis who did not respond to standard treatments. The treatment protocol included leukapheresis followed by fludarabine, cyclophosphamide, and infusion of C-CAR168.
- Tags
- #MSResearch
- Most relevant to
- —
- Source
- Read original source
This plain-English summary was written by AI from a trial registry record and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
- Human efficacy
- Not yet assessed
- Mechanism
- Not yet assessed
- Evidence strength
- Not yet assessed
- Outcome
- Not yet assessed
Why it matters
This research aims to address the needs of patients with progressive MS who lack effective treatment options, potentially leading to new therapeutic strategies.
What this does not prove
No study results have been posted, and the planned endpoints do not provide findings.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Not reported
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- Not reported
- Evidence reviewed
- Trial registry record
- Regulatory approval
- Not reported
- Research areas
- Not classified
Original sources
Supporting passages (6)
study phase"briefSummary": "This is a global, multicenter, Phase 1b/2 study evaluating the safety and efficacy of C-CAR168, an autologous anti-CD20/BCMA chimeric antigen receptor T-cell therapy, in participants with progressive multiple sclerosis refractory to standard-of-care therapy.
subjects"briefSummary": "This is a global, multicenter, Phase 1b/2 study evaluating the safety and efficacy of C-CAR168, an autologous anti-CD20/BCMA chimeric antigen receptor T-cell therapy, in participants with progressive multiple sclerosis refractory to standard-of-care therapy.
intervention"description": "Participants will receive:\n\nLeukapheresis Fludarabine Cyclophosphamide Single intravenous infusion of C-CAR168",
primary endpoint"description": "Incidence and severity of treatment-emergent adverse events, serious adverse events, dose-limiting toxicities, CRS, ICANS, adverse events of special interest, and treatment- or procedure-related adverse events.",
findings"briefSummary": "This is a global, multicenter, Phase 1b/2 study evaluating the safety and efficacy of C-CAR168, an autologous anti-CD20/BCMA chimeric antigen receptor T-cell therapy, in participants with progressive multiple sclerosis refractory to standard-of-care therapy.
limitationsPlanned enrolment and endpoints are not findings.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.